Biogen Inc. Stock Climbs 4.2%, Outperforms Peers

Dow Jones10-21

This article was automatically generated by Dow Jones using technology from Automated Insights.

Shares of Biogen Inc. advanced 4.2% to $243.24 on what proved to be an all-around favorable trading session for the stock market, with the S&P 500 Index rising 0.3% to 7,712.57 and the Dow Jones Industrial Average rising 1.0% to 52,495.88.

This was the stock's second consecutive day of gains.

Biogen Inc. hit a new 52-week high, surpassing its previous peak of $240.99, which the company reached on October 15th.

The stock outperformed some of its peers, as Johnson & Johnson rose 2.2% to $259.36, Pfizer Inc. rose 2.3% to $30.11, and AbbVie Inc. rose 2.26% to $289.08.

Trading volume totaled 1.5 million, compared to the 50-day average of 980,822.

Data source: Dow Jones Market Data, FactSet

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment